Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis

International Journal of Cardiology

Volumn 181, Issue , 2015, Pages 239-244

  Savarese, Gianluigi ^a,b   Perrone Filardi, Pasquale ^a   D'Amore, Carmen ^a   Vitale, Cristiana ^b   Trimarco, Bruno ^a   Pani, Luca ^c   Rosano, Giuseppe M C ^b,d  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c ITALIAN MEDICINES AGENCY   (Italy)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cardiovascular; Diabetes mellitus; Heart failure; Prognosis DPP 4 inhibitors

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; PLACEBO;

ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EFFICACY; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; META ANALYSIS; MORBIDITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; PROCEDURES; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG ADMINISTRATION SCHEDULE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84932619134     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.12.017     Document Type: Article

References (23)

1. International Diabetes Federation Global burden: prevalence and projections, 2011 and 2030 Available from http://www.diabetesatlas.org/content/diabetes-and-impairedglucose-tolerance 2011
2. W.B. Kannel, M. Hjortland, and W.P. Castelli Role of diabetes in congestive heart failure: the Framingham study Am. J. Cardiol. 34 1974 29 34
3. A. Varela-Roman, L. Grigorian Shamagian, E. Barge Caballero, P. Mazon Ramos, P. Rigueiro Veloso, and J.R. Gonzalez-Juanatey Influence of diabetes on the survival of patients hospitalized with heart failure: a 12-year study Eur. J. Heart Fail. 7 2005 859 864
4. C. Iribarren, A.J. Karter, A.S. Go, A. Ferrara, J.Y. Liu, S. Sidney, and J.V. Selby Glycemic control and heart failure among adult patients with diabetes Circulation 103 2001 2668 2673
5. E. Ingelsson, J. Sundström, J. Arnlöv, B. Zethelius, and L. Lind Insulin resistance and risk of congestive heart failure JAMA 294 2005 334 341
6. B. Hemmingsen, S.S. Lund, C. Gluud, A. Vaag, T. Almdal, C. Hemmingsen, and J. Wetterslev Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus Cochrane Database Syst. Rev. 11 2011 CD008143
7. Food and Drug Administration, and Center for Drug Evaluation and Research Guidance for industry: diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes Available on http://www.fda.gov/downloads/Drugs/Guidance%20Compliance%20Regulatory%20Information/Guidances/ucm071627.pdf
8. European Medicines Agency Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus Available on http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/06/WC500129256.pdf
9. B.M1. Scirica, D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, B. Hirshberg, P. Ohman, R. Frederich, S.D. Wiviott, E.B. Hoffman, M.A. Cavender, J.A. Udell, N.R. Desai, O. Mosenzon, D.K. McGuire, K.K. Ray, L.A. Leiter, I. Raz, and SAVOR-TIMI 53 Steering Committee and Investigators Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N. Engl. J. Med. 369 2013 1317 1326
10. J. McMurray The Vildagliptin in Ventricular Dysfunction Diabetes trial (VIVIDD) Presented at the European Heart Failure Meeting, Lisbon, May 2013 2013
11. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, and PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement J. Clin. Epidemiol. 62 2009 1006 1012
12. S. Sharp, and J. Sterne Meta-analysis STB Repr. 7 1998 100 108
13. A. Whitehead Meta-analysis of Controlled Clinical Trials 2002 John Wiley & Sons Inc. Chichester, England
14. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. Identifying and measuring heterogeneity http://handbook.cochrane.org/
15. J.L. Peters, A.J. Sutton, D.R. Jones, K.R. Abrams, and L. Rushton Comparison of two methods to detect publication bias in meta-analysis JAMA 295 2006 676 680
16. W.B. White, C.P. Cannon, S.R. Heller, S.E. Nissen, R.M. Bergenstal, G.L. Bakris, A.T. Perez, P.R. Fleck, C.R. Mehta, S. Kupfer, C. Wilson, W.C. Cushman, F. Zannad, and EXAMINE Investigators Alogliptin after acute coronary syndrome in patients with type 2 diabetes N. Engl. J. Med. 369 2013 1327 1335
17. D.J. Drucker, and M.A. Nauck The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-IV inhibitors in type 2 diabetes Lancet 368 2006 1696 1705
18. A. Berhan, and Y. Berhan Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies BMC Endocr. Disord. 13 2013 9
19. K.L. Wang, C.J. Liu, T.F. Chao, C.M. Huang, C.H. Wu, S.J. Chen, C.M. Yeh, T.J. Chen, S.J. Lin, and C.E. Chiang Sitagliptin and the risk of hospitalization for heart failure: a population-based study Int. J. Cardiol. 177 2014 86 90
20. S. Agarwal, A. Parashar, and V. Menon Meta-analysis of the cardiovascular outcomes with dipeptidyl peptidase 4 inhibitors: validation of the current FDA mandate Am. J. Cardiovasc. Drugs 14 2014 191 207
21. M. Monami, B. Ahrèn, I. Dicembrini, and E. Mannucci Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials Diabetes Obes. Metab. 15 2013 112 120
22. S. Wu, I. Hopper, M. Skiba, and H. Krum Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants Cardiovasc. Ther. 32 2014 147 158
23. A. Marney, S. Kunchakarra, L. Byrne, and N.J. Brown Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans Hypertension 56 2010 728 733